The loss of muscle mass with aging was first recognized by MacDonald Critchley. Rosenberg felt that "no decline with age is more dramatic or potentially more functionally significant than the decline in muscle mass" and suggested that it needed a name derived from the Greek-sarcopenia (ie, flesh loss). 1,2 Baumgartner et al 3 provided an operational definition using a definition based on muscle mass corrected for height, and defined, similarly to osteoporosis, as being 2 standard deviations below the level of healthy young persons. With the advent of an operational definition, consensus began to be lost. Generally it is recognized that sarcopenia is reduced muscle mass that leads to negative effects on function and clinical outcome.
Muscle mass declines at approximately 1% per year after the age of 30 years. Severe muscle loss (ie, 2 standard deviations below healthy young) is present in 5% to 13% of 60-to 70-year-olds and 11% to 50% of those 80 and older. [4] [5] [6] This loss of muscle mass has been shown to be associated with disability in some studies. However, the development of disability is a complex area and is almost always multifactorial in older persons. At the end of 2010, more than 1000 publications had appeared in PubMed using the definition of sarcopenia, as age-related muscle loss below 2 standard deviations of the mean for young persons. Multiple factors leading to sarcopenia have been identified [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] (Figure 1 ).
Although the definition of sarcopenia based on loss of muscle mass alone has served the scientific community fairly well, it has been less satisfying for clinicians, the pharmaceutical industry, and regulatory agencies. Unlike the measurements of bone mineral density, the measurement of muscle mass has not been widely adopted by clinicians. Regulatory agencies have failed to accept that restoration of muscle mass is, of itself, a sufficient reason to allow a drug to be approved for use. It should be noted that this is not different from the situation with osteoporosis wherein reduced bone mineral density is recognized as a legitimate indication for treatment, but for regulatory considerations, drugs have had to show a reduction in fracture incidence before approval. [18] [19] [20] These factors/impediments have led to groups, originally from the European Union, and then from the European Union and the United States with industry support, to question the clinical feasibility of the original definition, and efforts to redefine sarcopenia have been advanced. 4, 21, 22 In an attempt to find a consensus, the Society for Sarcopenia, Cachexia and Wasting Disorders convened a meeting in Washington, DC, in December 2010, with participants with multiple viewpoints. The purpose of the meeting was to find a definition or set of definitions that is universally acceptable and can lead to easily definable end points for clinical trials. It was hoped that the definition developed would
•
Be a meaningful surrogate for clinically useful end points, eg, decline in activities of daily living, hospitalization, nursing home residence, injurious falls, or mortality.
• Allow for treatments that worked in ways different from increasing muscle mass.
• Include only measurements that have been demonstrated to lead longitudinally to clinically meaningful outcomes and have definable cut points based on data.
• Be independent of the molecular target(s) for drug development.
THE POWER-STRENGTH-MASS CONUNDRUM
Muscle mass is the primary determinant of strength. Males are generally stronger than females primarily because they have larger muscle mass. Loss of strength tends to track with loss of muscle mass with aging in physiological studies, although the decline in muscle strength is steeper than the decline in muscle mass. 23, 24 However, interventions that increase muscle mass do not necessarily increase strength. 25 Conversely, changes in strength that occur with resistance training precede measurable changes in muscle mass temporally and exceed them in size. 26 Loss in strength is not necessarily present with voluntary weight loss despite the associated loss of skeletal muscle. 27 Correlations between change in muscle mass and change in strength in older adults are inconsistent and not very robust. 28 One reason for this inconsistency is the infiltration into muscle by fat, which is a powerful predictor of future disability and mortality. 29 This has been designated as sarcopenic obesity, myosteatosis, or the "fat frail." [30] [31] [32] [33] [34] Infiltration of collagen into muscle with aging can also lead to a dichotomy in the relationship between muscle mass and strength. 35 Age-associated changes in neuromuscular activation that are superimposed on changes in muscle mass may further explain the dichotomy between mass and strength/power losses. 36, 37 Finally, alterations in the angle of pennation by which tendons insert into muscle can markedly alter power. [38] [39] [40] Other changes in muscle leading to a loss of strength include deposition of abnormal proteins; contractile and structural protein misfolding; and mitochondrial, neuromuscular, and plaque dysfunction.
There is a logical series of classics-derived descriptions of muscle changes that result in loss of muscle mass (sarcopenia), loss of muscle strength (kratopenia, named for the Greek god of strength, Kratos), loss of power (dynopenia), and frailty (Table 1) . Like sarcopenia, a number of different definitions for frailty have been developed (Table 2) . [41] [42] [43] [44] [45] [46] [47] [48] [49] With the exception of the Rockwood et al 46 definition, all the definitions include both strength and weight loss.
A final problem with the definition of sarcopenia is the variety of measures available to measure muscle mass. Each of these leads to slightly different cutoffs for muscle mass and are indirect measures. As such, they can be influenced by adiposity and total body water. [50] [51] [52] These different measures are compared in Table 3 . Newer mechanisms such as the 13 C-creatine dilution method may solve some of these problems.
VALIDITY OF END POINTS
A number of studies have shown that muscle mass less than 2 standard deviations of that of a healthy young adult is predictive of disability and mortality. 9, 34, [53] [54] [55] [56] [57] [58] [59] [60] At present there is no clear consensus pertaining to the magnitude of change in muscle mass that is predictive of clinically meaningful outcomes. To determine appropriate appendicular muscle mass values to predict outcomes requires a standardization using each of the instruments used to measure muscle mass. Standardization against healthy young controls 20 to 30 years of age needs to be developed for individual ethnic groups, similar to those developed for osteoporosis in the FRAX Index (www.shef.ac.uk/FRAX). A minimum of 100 control individuals needs to be included in each cohort. Development of cut points needs to exclude persons with limb pain or substantial balance problems.
Usual gait speed over a variety of distances from 4 to 6 meters has been shown to be predictive for the onset of disability, severe mobility limitation, hospitalization, and mortality. [61] [62] [63] [64] [65] Gait speeds equal to or less than 1 m/s appear to be equally predictive of poor outcomes. A clinically significant improvement in gait speed is at least 0.1 m/s. [65] [66] [67] [68] The 6-minute walking test has been used as a measure for drug approval by several regulatory agencies for the assessment of drugs for the treatment of peripheral vascular disease and pulmonary hypertension. The 6-minute walk test is highly predictive of hospitalization and mortality in medically ill persons. [69] [70] [71] [72] [73] A cutoff of 400 m has been established. 69, 74, 75 In persons who can walk at least 100 m, a clinically significant change has been found to be more than 50 meters. 69 
DEFINITION
It was decided that "sarcopenia with limited mobility" would be an acceptable term to define persons with a need for therapeutic interventions. This is a specific condition with clear loss of muscle mass and a clear target for intervention. As such, it differs from the more general concept of frailty. The definition is based on consensus and may change as additional data come available. "Sarcopenia with limited mobility" is a syndrome not a disease.
Sarcopenia with limited mobility is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk. The person should also have a lean appendicular mass corrected for height squared of more than 2 standard deviations below that of healthy persons between 20 and 30 years of age of the same ethnic group. The cutoffs determined are arbitrary, as the associations with mass and gait speed with disability are continuous. The limitation in mobility should not be clearly attributable to the direct effect of specific disease, such as peripheral vascular disease with intermittent claudication, or central or peripheral nervous system disorders (such as stroke, Parkinson's disease, spinal cord disease, or motor neuron disease), dementia, or cachexia. [80] [81] [82] [83] Interventions that are considered clinically significant are an increase in the 6-minute walk of 50 meters or an increase of gait speed of 0.1 m/s. Sarcopenia is generally believed to be age-associated and its prevalence increases with aging. Research needs to establish that change in gait speed owing to therapy aimed at sarcopenia will reduce disability and that the amount of change in gait speed will predict the improvement in outcome.
It is important to recognize that sarcopenia can overlap with many of the specifically excluded conditions; and that exercise, nutrition, and other treatments that decrease sarcopenia may be useful in these conditions. [84] [85] [86] There was no consensus among the panel of whether sarcopenia as a term should be limited to use in older persons (60+ years of age) or used as a general term for adults of any age. A minority support the use of the term "myopenia" to indicate the presence of clinically relevant muscle wasting owing to any illness at any age, 87, 88 with "sarcopenia" being limited to use for older persons. Sarcopenia has been generally recognized as an age-related process of multiple etiologies; however, nephrologists tend to use the term for persons with chronic kidney disease and dialysis patients with protein energy wasting and muscle wasting regardless of age. Thus, although emphasizing that this is a common condition in older age, the panel was not comfortable in limiting the definition to only older persons. There is a need to determine the role of executive function decline in the development of sarcopenia with limited mobility. [89] [90] [91] At present, fast gait speed and inability to carry out "dual tasking" appear to separate executive function mobility disorders. We recommend that all patients older than 60 years who are falling, who feel that their walking speed has decreased, who have had a recent hospitalization, who have been on prolonged bed rest, who have problems arising from a chair, or who need to use an assistive device for walking are screened for sarcopenia with mobility impairment. As has been previously suggested, gait speed or distance traveled during a 6-minute walk should be measured in all these patients, and this mobility measure should be separately reimbursed from the regular physician visit. 92 The decision about whether to treat should be based on absolute risk of an adverse clinical outcome, such as mobility disability, and the absolute decrease in risk from treatment. Sarcopenia may be only one of several risk factors to be used in treatment decisions. Although recognizing that clinical trials in older persons with "sarcopenia with limited mobility" are challenging, there is a wonderful opportunity to develop new drugs that may greatly enhance the quality of life of older persons. 93
Fig. 1.
Factors involved in the pathophysiology of sarcopenia. It is important to recognize these are limited studies often only in one ethnic group and are given purely as examples.
